RET and non-small cell lung carcinoma: Similarly, MET amplification has been found in patients with RET fusion positive NSCLC progressing on selpercatinib or pralsetinib (Lin et al. 2020, Rosen et al. 2021, 2022, Zhu et al. 2021) (Fig. 3).